RA CAPITAL MANAGEMENT, L.P.
Q4 2019 13F-HR Holdings
Net value change ($000)
—
New positions
34
Sold out positions
0
Turnover %
100.0%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to previous filing: —
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Synthorx, Inc. | 679,652 | — |
| ASND | 582,265 | — |
| Ra Pharmaceuticals, Inc. | 227,998 | — |
| ARVN | 150,918 | — |
| ChemoCentryx, Inc. | 126,536 | — |
| RYTM | 124,496 | — |
| Eidos Therapeutics, Inc. | 124,116 | — |
| ZOGENIX, INC. | 117,853 | — |
| PHAT | 113,562 | — |
| TGTX | 109,672 | — |
Top Reduces (Value $000, Stocks/ETFs)
| — |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|